The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab ; volume:84 ; number:12 ; day:13 ; month:11 ; year:2024 ; pages:1579-1601 ; date:12.2024
Drugs ; 84, Heft 12 (13.11.2024), 1579-1601, 12.2024
- Creator
-
Kester, Robert
Zalani, Sunita
Ebbinghaus, Scot
Rubin, Eric
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02111-7
- URN
-
urn:nbn:de:101:1-2503012104066.445273652790
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kester, Robert
- Zalani, Sunita
- Ebbinghaus, Scot
- Rubin, Eric
- SpringerLink (Online service)
Other Objects (12)
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval
Pexidartinib: First Approval
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval
Pexidartinib: First Approval
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval